Apraglutide

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals is a commercial-stage biotech with a singular focus on gastrointestinal health, leveraging deep GI expertise to redefine the standard of care. Its flagship product, LINZESS, is a blockbuster GC-C agonist for IBS-C and CIC, establishing the company's commercial foundation. The company's strategic direction involves expanding its pipeline through targeted acquisitions, like VectivBio for apraglutide, to address severe GI conditions with high unmet need, such as Short Bowel Syndrome with intestinal failure (SBS-IF).

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals is a commercial-stage biotech with a singular focus on gastrointestinal health, leveraging deep GI expertise to redefine the standard of care. Its flagship product, LINZESS, is a blockbuster GC-C agonist for IBS-C and CIC, establishing the company's commercial foundation. The company's strategic direction involves expanding its pipeline through targeted acquisitions, like VectivBio for apraglutide, to address severe GI conditions with high unmet need, such as Short Bowel Syndrome with intestinal failure (SBS-IF).

Therapeutic Areas